Open Interest and Volume Dynamics
On 15 Jul 2026, Mankind Pharma’s open interest (OI) in derivatives rose sharply by 2,866 contracts, a 14.72% increase from the previous day’s 19,470 to 22,336. This surge in OI was accompanied by a robust volume of 55,137 contracts, reflecting heightened trading activity and fresh positions being established. The futures segment alone accounted for a value of approximately ₹27,899.65 lakhs, while options contributed an overwhelming ₹34,053.27 crores in notional value, culminating in a total derivatives value of ₹35,207.12 lakhs.
Such a pronounced increase in OI alongside elevated volumes typically indicates that new money is flowing into the stock, rather than existing positions merely rolling over. This suggests that market participants are actively taking directional bets on Mankind Pharma’s price trajectory.
Price Performance and Technical Context
Mankind Pharma’s underlying share price has mirrored this positive sentiment, gaining 1.22% on the day to close near ₹2,572. The stock outperformed its Pharmaceuticals & Biotechnology sector, which rose by 0.71%, and the broader Sensex, which advanced 0.19%. Notably, the stock has recorded gains for two consecutive sessions, delivering a cumulative return of 2.32% over this period.
Intraday, Mankind Pharma touched a high of ₹2,639, marking a 4.26% rally from the previous close. The stock is trading comfortably above its key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — signalling a sustained bullish trend and strong technical support.
However, delivery volumes have declined by 11.1% compared to the 5-day average, with 1.49 lakh shares delivered on 14 Jul. This drop in investor participation at the delivery level may indicate that short-term traders and derivatives players are driving the recent momentum rather than long-term holders.
This week's disclosed pick, a Large Cap from NBFC, comes with precise Target Price and analysis. Check if you're positioned right for this opportunity!
- - Precise target price set
- - Weekly selection live
- - Position check opportunity
Market Positioning and Directional Bets
The sharp rise in open interest combined with strong volume suggests that traders are increasingly bullish on Mankind Pharma’s near-term prospects. The increase in futures value to nearly ₹27,900 lakhs indicates that participants are taking sizeable long positions, anticipating further price appreciation.
Options market data, with an enormous notional value exceeding ₹34,000 crores, points to active hedging and speculative activity. The elevated options interest may be concentrated around key strike prices near the current underlying value of ₹2,572, reflecting a market consensus on potential price ranges and volatility expectations.
Given the stock’s recent outperformance relative to its sector and the Sensex, the derivatives activity may be driven by institutional investors and proprietary trading desks positioning for continued momentum. The Mojo Score of 65.0 and a current Mojo Grade of Hold, downgraded from Buy on 1 Jul 2026, suggests a cautious stance from fundamental analysts, possibly due to valuation concerns or sector headwinds. Nonetheless, the technical and derivatives signals point to a positive short-term bias.
Liquidity and Trading Considerations
Mankind Pharma’s liquidity profile remains robust, with the stock’s traded value comfortably supporting trade sizes up to ₹1.63 crores based on 2% of the 5-day average traded value. This liquidity ensures that institutional investors can enter or exit positions without significant market impact, further encouraging active derivatives participation.
Investors should note the divergence between rising derivatives activity and falling delivery volumes, which may imply that the recent price gains are primarily driven by speculative flows rather than fundamental buying. This dynamic warrants close monitoring, as a reversal in derivatives positioning could lead to increased volatility.
Mankind Pharma Ltd or something better? Our SwitchER feature analyzes this mid-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Outlook and Investor Implications
While Mankind Pharma’s recent derivatives activity and price action indicate a bullish near-term outlook, investors should weigh this against the fundamental assessment reflected in the Hold rating and the recent downgrade from Buy. The mid-cap pharmaceutical company, with a market capitalisation of approximately ₹1,05,813.70 crores, operates in a sector subject to regulatory risks and competitive pressures.
Traders may consider the current momentum as an opportunity for tactical gains, especially given the stock’s strong technical positioning above all major moving averages. However, longer-term investors should remain cautious and monitor delivery volumes and open interest trends closely to gauge the sustainability of this rally.
In summary, the surge in open interest and volume in Mankind Pharma’s derivatives signals increased market confidence and directional bets favouring upside potential. Yet, the mixed fundamental signals and reduced investor participation at the delivery level counsel prudence.
Key Metrics at a Glance:
- Open Interest: 22,336 contracts (up 14.72%)
- Volume: 55,137 contracts
- Futures Value: ₹27,899.65 lakhs
- Options Value: ₹34,053.27 crores
- Underlying Price: ₹2,572
- Market Cap: ₹1,05,813.70 crores (Mid Cap)
- Mojo Score: 65.0 (Hold, downgraded from Buy on 1 Jul 2026)
- Price Performance: +1.22% (1-day), +2.32% (2-day gain)
Investors should continue to monitor open interest trends and volume patterns in conjunction with price action to better understand evolving market sentiment towards Mankind Pharma.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
